ClinicalTrials.gg
RecruitingNCT06651697BEFOREUpdated Feb 17, 2026

BladdEr Full OR Empty for Pelvic Radiation Therapy

A Phase 3 interventional study of Radiation therapy in Pelvic Neoplasm, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University of California, San Diego · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Pelvic Neoplasms with a site in United States — 5 open to participants now, 9 under way, 2 of them phase 3. Pelvic Neoplasms · United States.

Planned enrollment
2nd of 20
300 · median 38
Started
2024
with 2 others
Phase 3
4 of 28
2 open now
Registered
25th of 28
by date

Among the 28 studies in Pelvic Neoplasms with a site in United States, this one is the 2nd largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 3, and was the 25th registered.

Pelvic Neoplasms

82 studies on the registry are indexed under Pelvic Neoplasms; 28 are open to participants now.

Browse Pelvic Neoplasms studies →

Open to participants now

5 of the 28 studies in Pelvic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Pelvic Neoplasms studies recruiting now, 16 (70%) set no upper age limit and 3 (13%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Pelvic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The present study evaluates empty and full bladder protocols for radiation therapy of genitourinary (GU), gynecological (Gyn), and gastrointestinal (GI) malignancies of the pelvis.

Read the detailed description

Pelvic radiation therapy plays a key role in the treatment of common genitourinary (GU), gynecological (Gyn), and gastrointestinal (GI) malignancies of the pelvis. Prior to starting a course of radiation therapy, patients undergo a CT simulation that allows for computer-based optimization of radiation dose delivery to target while simultaneously minimizing dose to surrounding normal tissues, such as the bladder and rectum. Commonly, physicians instruct patients undergoing pelvic radiation therapy to present with a reproducibly full bladder for the simulation and for each subsequent treatment session with the hope that increased distance between normal tissues (anterior bladder wall and bowel) and treatment target will limit toxicity. However, treating with a full bladder can result in wide variations in bladder volume. Often patients are unable to reproduce the bladder distention achieved at simulation, especially as typical urinary symptoms related to radiation develop during treatment. As the initial CT simulation is used to calculate dose distribution, bladder volume changes can affect radiation dose distribution to the bladder itself as well as adjacent pelvic organs. Given the challenges and uncertainties of treating with a full bladder, there has been increasing interest in bladder empty protocols. Retrospective, non-randomized, single-institution studies demonstrate that bladder empty protocols reduced absolute variation in bladder volume during treatment, had minimal impact on treatment related toxicity, and had non-inferior biochemical progression free survival, GI toxicities, and GU toxicities. However, prospective data is very limited. The present study plans to fill this knowledge gap by randomizing study participants to empty and full bladder protocols for simulation and radiation therapy.

03

Conditions studied

  • Pelvic Neoplasm

Browse trials for

Keywords

  • malignancy of the pelvis
  • bladder
  • radiation therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Persons, aged at least 18 years
  • Deemed eligible to undergo curative intent radiation therapy for primary GU, GI, or Gyn of the pelvis.
  • For participants able to become pregnant: use of highly effective for at least 1 month prior to screening and agreement to use such a method during study participation
  • For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Tumor invading the bladder, as judged by the enrolling physician based on available clinical information
  • to radiotherapy, including Crohn's disease and active connective tissue disorders such as scleroderma or uncontrolled lupus
  • Prior radiation therapy to an area requiring treatment in the present study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Full bladder

    Full bladder protocol for participants undergoing radiation therapy to pelvis for common malignancies.

    Radiation: Radiation therapy

  • Experimental
    Empty bladder

    Empty bladder protocol for participants undergoing radiation therapy to pelvis for common malignancies.

    Radiation: Radiation therapy

Interventions

  • RadiationRadiation therapy

    Radiation therapy with full bladder or empty bladder protocols

06

What researchers measure

Primary outcomes

  1. Acute toxicity

    Acute any attribution GU and/or GI grade ≥2 toxicity. This will be defined as the percentage of patients with CTCAE version 5.0 GU and/or GI grade ≥2 toxicity within 3 months post radiation therapy. This will be defined as a co-primary endpoint.

    Time frame: 3 months post radiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make individual participant data (IPD) available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Apr 2028, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2024
First posted
Oct 22, 2024
StartActual
Nov 19, 2024
Primary completionEst.
Apr 2028
CompletionEst.
Dec 2029
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06651697
Responsible party
Tyler Seibert (Radiation Oncologist, Associate Professor, University of California, San Diego) — Principal investigator
First posted
Oct 22, 2024
Start date
Nov 19, 2024
Primary completion
Apr 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Feb 17, 2026

Study contacts

Tyler Seibert, MD, PhD
Contact
CancerCTO@health.ucsd.edu
858 822 5354
Rana McKay, MD
Contact
CancerCTO@health.ucsd.edu
858 822 5354
Tyler Seibert, MD, PhD
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion